Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/6/2018
SIETES contiene 92381 citas

 
 
 1 a 20 de 1242 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Grant PJ, Conlon A, Chopra V, Flanders SA. Use of venous thromboembolism prophylaxis in hospitalized patients. JAMA Intern Med 2018:21 de mayo. [Ref.ID 102646]
3.Enlace a cita original Cita con resumen
Pincus D, Ravi B, Wassertein D, Huang A, Paterson JM, Nathens AB, Kreder HJ, Jenkinson RJ, Wodchis WP. Association between wait time and 30-day mortality in adults undergoing hip fracture surgery. JAMA 2017;318:1994-2003. [Ref.ID 102171]
4. Cita con resumen
Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P, for the EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017;376:1211-22. [Ref.ID 101509]
5.Enlace a cita original Cita con resumen
Martinez C, Suissa S, McGill J, Rietbrock S, Katholing A, Freedman B, Cohen AT, Handelsman DJ. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ 2016;355:i5968. [Ref.ID 101016]
6.Tiene citas relacionadas Cita con resumen
Righini M, Galanaud J-P, Guenneguez H, Brisot D, Diard A, Faisse P, Barrellier M-T, Hamel-Desnos C, Jurus C, Pichot O, Martin M, Mazzolai L, Choquenet C, Accassat S, Robert-Ebadi H, Carrier M, Le Gal G, Mermillod B, Laroche J-P, Bounameaux H, Perrier A, Kahn SR, Quere I. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. The Lancet Haematology 2016:noviembre. [Ref.ID 100906]
7.Enlace a cita originalTiene citas relacionadas Cita con resumen
Schellong SM. Low risk is not enough: the dilemma of calf vein thrombosis. The Lancet Haematology 2016:7 de noviembre. [Ref.ID 100905]
8. Cita con resumen
Nielen JTH, Dagnelie PC, Emans PJ, Veldhorst-Janssen N, Lalmohamed A, Van Staa T-P, Boonen AERCH, van den Bemt BJF, de Vries F. Safety and efficacy of new oral anticoagulants and low-molecular-weight heparins compared with aspirin in patients undergoing total knee and hip replacements. Pharmacoepidemiol Drug Saf 2016;25:1245-52. [Ref.ID 100896]
9. Cita con resumen
Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM, for the APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016;375:534-44. [Ref.ID 100706]
10. Cita con resumen
Utter GH, Dhillon TS, Salcedo ES, Shouldice DJ, Reynolds CL, Humphries MD, White RH. Therapeutic anticoagulation for isolated calf deep vein thrombosis. JAMA Surgery 2016:20 de julio. [Ref.ID 100578]
11. Cita con resumen
Anónimo. Édoxaban. Prescrire 2016;36:486-7. [Ref.ID 100546]
12. Cita con resumen
Mol GC, van de Ree MA, Flok FA, Tegelberg MJAM, Sanders FBM, Koppen S, de Weerdt O, Koster T, Hovens MMC, Kaasjager HAH, Brouwer RE, Kragten E, Schaar CG, Spiering W, Arnold WP, Biesma DH, Huisman MV. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. BMJ 2016;353:i2691. [Ref.ID 100418]
13. Cita con resumen
Husted S, Verheugt FWA, Comuth WJ. Reversal strategies for NOACs: state of development, possible clinical applications and future perspectives. Drug Saf 2016;39:5-13. [Ref.ID 100083]
14. Cita con resumen
Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ 2015;351:h4847. [Ref.ID 99595]
15. Cita con resumen
Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Jüni P, Vranckx P, for the MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015;373:997-1009. [Ref.ID 99531]
16.Tiene citas relacionadas Cita con resumen
Brotman DJ, Streiff MB. Overuse of bridging anticoagulation for patients with venous thromboembolism. First, do no harm. JAMA Intern Med 2015;175:julio. [Ref.ID 99097]
17.Tiene citas relacionadas Cita con resumen
Clark NP, Witt DM, Davies LE, Saito EM, McCool KH, Douketis JD, Metz KR, Delate T. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med 2015;175:1163-8. [Ref.ID 99096]
18. Cita con resumen
Hernández I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2014;175:18-24. [Ref.ID 98701]
19. Cita con resumen
Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH, for the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-58. [Ref.ID 98362]
20. Cita con resumen
Redberg RS. The importance of postapproval data for dabigatran. JAMA Intern Med 2015;175:25. [Ref.ID 98317]
Seleccionar todas
 
 1 a 20 de 1242 siguiente >>